Standout Papers

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal G... 2019 2026 2021 2023 335
  1. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study (2019)
    Yukio Hosomi, Satoshi Morita et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 12 from Science/Nature 67 standout
Sub-graph 1 of 21

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
18 intermediate papers

Works of Koichi Minato being referenced

Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).
2018
Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03
2009
and 1 more

Author Peers

Author Last Decade Papers Cites
Koichi Minato 2011 1533 244 771 170 3.0k
Young Hak Kim 1870 1647 289 638 126 2.8k
Sun Min Lim 1431 1576 221 879 130 2.7k
Paolo Maione 2164 1994 230 1082 138 3.6k
Hidehito Horinouchi 1910 1602 261 475 218 2.9k
Sara Pilotto 1735 1042 313 796 179 2.8k
Adolfo Favaretto 1670 2108 357 760 135 3.6k
Taishi Harada 1468 1341 190 844 113 2.6k
Diego Cortinovis 2141 1387 101 579 178 3.3k
Kostas Syrigos 1614 1080 208 1005 113 3.2k
Paolo Bidoli 1921 1843 184 526 126 3.0k

All Works

Loading papers...

Rankless by CCL
2026